Fulgent Reports First Quarter 2024 Financial Results

Total Revenue of $64.5 million



Core Revenue grows 1% year-over-year to $63.2 million



Reiterates Full Year 2024 Core Revenue Guidance of $280 million


...

Related Keywords

United States ,America ,Paul Kim ,Ming Hsieh ,Exchange Commission ,Nasdaq ,Fulgent Genetics Inc ,Fulgent Genetics ,Score Revenue ,Chief Executive Officer ,Precision Diagnostics ,Investigational New Drug ,Chief Financial Officer ,Investor Relations ,Private Securities Litigation Reform Act ,Consolidated Statement ,Months Ended March ,